Ucb SA logo

UCB - Ucb SA News Story

€79.26 -1.7  -2.1%

Last Trade - 12/04/21

Sector
Healthcare
Size
Large Cap
Market Cap £13.28bn
Enterprise Value £14.23bn
Revenue £4.64bn
Position in Universe 58th / 847

BRIEF-UCB: BE VIVID, BE READY Data Showed Both Studies Met Co-Primary Endpoints

Fri 5th February, 2021 6:14am
Feb 5 (Reuters) - Ucb SA  UCB.BR :
    * DATA FROM BE VIVID AND BE READY SHOWED THAT BOTH STUDIES
MET
THEIR CO-PRIMARY ENDPOINTS
    * DATA FROM BE VIVID AND BE READY STUDIES WERE INCLUDED IN
MARKETING APPLICATION SUBMISSIONS TO FDA AND EMA
    * SAFETY AND EFFICACY OF BIMEKIZUMAB HAVE NOT BEEN
ESTABLISHED AND
IT IS NOT APPROVED BY ANY REGULATORY AUTHORITY WORLDWIDE.
    * BIMEKIZUMAB IS CURRENTLY UNDER REVIEW BY (FDA) AND (EMA)
FOR
TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN ADULTS

Source text: https://cisn.co/3ttwINe
Further company coverage:  UCB.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.